CD200 is a new prognostic factor in multiple myeloma.
作者： J. Moreaux , D. Hose , T. Reme , E. Jourdan , M. Hundemer
DOI: 10.1182/BLOOD-2006-06-029355
关键词:
摘要: Using Affymetrix microarrays, we identified the expression of CD200 gene in multiple myeloma cells (MMCs) 112 patients with newly diagnosed (MM). The was either absent or present (Affymetrix call) 22% and 78% MMCs, respectively. is not expressed patients' bone marrow (BM). a membrane glycoprotein that imparts an immunoregulatory signal through CD200R, leading to suppression T-cell-mediated immune responses. Patients CD200(absent) MMCs have increased event-free survival (EFS; 24 months) compared CD200(present) (14 months), after high-dose therapy stem cell transplantation. In Cox proportional-hazard model, absence presence predictive for EFS independently ISS stage beta2M serum levels. Thus, independent prognosis factor MM could represent new therapeutic target MM.
ashpublications.org
bloodjournal.org
archives-ouvertes.fr参考文章(18)
Reginald M Gorczynski, CD200 and its receptors as targets for immunoregulation. Current opinion in investigational drugs. ,vol. 6, pp. 483- 488 ,(2005)
XG Zhang, JP Gaillard, N Robillard, ZY Lu, ZJ Gu, M Jourdan, JM Boiron, R Bataille, B Klein, Reproducible Obtaining of Human Myeloma Cell Lines as a Model for Tumor Stem Cell Study in Human Multiple Myeloma Blood. ,vol. 83, pp. 3654- 3663 ,(1994) , 10.1182/BLOOD.V83.12.3654.3654
Gavin J. Wright, Holly Cherwinski, Mildred Foster-Cuevas, Gary Brooke, Michael J. Puklavec, Mike Bigler, Yaoli Song, Maria Jenmalm, Dan Gorman, Terri McClanahan, Man-Ru Liu, Marion H. Brown, Jonathon D. Sedgwick, Joseph H. Phillips, A. Neil Barclay, Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. Journal of Immunology. ,vol. 171, pp. 3034- 3046 ,(2003) , 10.4049/JIMMUNOL.171.6.3034
Reginald M. Gorczynski, Zhiqi Chen, Xin-Ming Fu, Hua Zeng, Increased expression of the novel molecule OX-2 is involved in prolongation of murine renal allograft survival. Transplantation. ,vol. 65, pp. 1106- 1114 ,(1998) , 10.1097/00007890-199804270-00016
Reginald M. Gorczynski, Lydia Lee, Ivo Boudakov, Augmented Induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. Transplantation. ,vol. 79, pp. 1180- 1183 ,(2005) , 10.1097/01.TP.0000152118.51622.F9
J. R. McWhirter, A. Kretz-Rommel, A. Saven, T. Maruyama, K. N. Potter, C. I. Mockridge, E. P. Ravey, F. Qin, K. S. Bowdish, Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 103, pp. 1041- 1046 ,(2006) , 10.1073/PNAS.0510081103
Bernard Klein, Karin Tarte, Michel Jourdan, Karene Mathouk, Jerome Moreaux, Eric Jourdan, Eric Legouffe, John De Vos, Jean François Rossic, Survival and proliferation factors of normal and malignant plasma cells. International Journal of Hematology. ,vol. 78, pp. 106- 113 ,(2003) , 10.1007/BF02983377
R.M Gorczynski, Z Cohen, X.M Fu, J Lei, Anti-rat OX-2 blocks increased small intestinal transplant survival after portal vein immunization. World Congress of the Transplantation Society. ,vol. 31, pp. 577- 578 ,(1999) , 10.1016/S0041-1345(98)01563-2
J-F Rossi, N Fegueux, Z Y Lu, E Legouffe, C Exbrayat, M-C Bozonnat, R Navarro, E Lopez, P Quittet, J-P Daures, V Rouillé, T Kanouni, J Widjenes, B Klein, Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplantation. ,vol. 36, pp. 771- 779 ,(2005) , 10.1038/SJ.BMT.1705138
A.Neil Barclay, Gavin J. Wright, Gary Brooke, Marion H. Brown, CD200 and membrane protein interactions in the control of myeloid cells Trends in Immunology. ,vol. 23, pp. 285- 290 ,(2002) , 10.1016/S1471-4906(02)02223-8